Removing the pharmaceutical market Myolastan

Myolastan 50mg
Myolastan 50mg

Myolastan known as the DCI used as muscle relaxant Tetrazepam during neuralgia and sciatica or back pain most commonly described by; will be withdrawn from the market after a study to demonstrate a significant risk of allergic skin reactions such as drug drug eruption Stevens-Johnson syndrome and dementia risk is a potential risk associated with all benzodiazepines as for Xanax, Valium and Temesta.

Myolastan 50mg

The Tetrazepam is commercialicé since 1969 in France and will soon be withdrawn from the market; from July 8, 2013 throughout the European union.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.